A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.
about
Optimal usage of the GnRH antagonists: a review of the literatureLong-acting FSH versus daily FSH for women undergoing assisted reproductionLong-acting FSH versus daily FSH for women undergoing assisted reproductionLong-acting FSH versus daily FSH for women undergoing assisted reproductionGnRH agonist for triggering of final oocyte maturation: time for a change of practice?Subcutaneous Progesterone Is Effective and Safe for Luteal Phase Support in IVF: An Individual Patient Data Meta-Analysis of the Phase III TrialsAn open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism.The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction.Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocolA new approach for ovarian stimulation in IVF using Corifollitropin Alfa in combination with GnRH analogues to trigger final oocyte maturation. A pilot studyClinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation.Gonadotrophins: The future.Incomplete and inconsistent reporting of maternal and fetal outcomes in infertility treatment trialsRepeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity.The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist.Efficacy and safety of late-start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case-control study.Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysisEfficacy of corifollitropin alfa followed by recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist protocol for Korean women undergoing assisted reproduction.Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist ProtocolA Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders.Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.Best practices for controlled ovarian stimulation in in vitro fertilizationPredictive factors for ovarian response in a corifollitropin alfa/GnRH antagonist protocol for controlled ovarian stimulation in IVF/ICSI cycles.Balancing selected medication costs with total number of daily injections: a preference analysis of GnRH-agonist and antagonist protocols by IVF patientsCorifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trialGnRH analogues in the prevention of ovarian hyperstimulation syndromeImpact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian stimulationCorifollitropin stimulation in combination with GnRH-antagonists after estradiol valerate pre-treatment. A pilot study on patientfriendly IVF.Effectiveness of corifollitropin alfa used for ovarian stimulation of poor responder patientsEvaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol.Poor responders in in vitro fertilization (IVF) therapy: the challenge continues.Corifollitropin alfa: a novel long-acting recombinant follicle-stimulating hormone agonist for controlled ovarian stimulation.Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction.Corifollitropin alfa for female infertility.FSH Stimulation promotes progesterone synthesis and output from human granulosa cells without luteinization.[In vitro fertilization and intracytoplasmic sperm injection: current medical aspects].Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
P2860
Q21245566-B5A191DF-9703-49C9-AE2B-7DD67AA943FCQ24186504-87C1CB22-9275-4B98-AD30-0C5647D651B0Q24202586-5DFE0B15-3AC2-42B7-A7E9-F9C9C1D188B9Q24203939-62201CF2-47D5-4936-AE5F-49E6E3CFB99BQ28308094-20C89A3F-FCD7-4E3A-AB35-B60AFD9D0902Q28550893-3EC22DD3-4E47-47D2-96A5-FE13CE446CD8Q30313362-26D70A44-C214-4DAE-8748-E161803D95E5Q33731989-2D1774B5-BC8A-4A18-A98A-F718B4E0DE43Q33807434-27C04CCF-F908-4BA0-B467-7CA2468FD5F6Q33888265-91DE62BE-9516-4E28-96FA-2B86D887AB3DQ34439774-61F5D054-EA97-4E8C-B52C-42FCB732A8FEQ34656033-EF39AB3E-DD05-4BF5-ABA4-6ECCCA4665BBQ34975528-7F8F3770-0D78-4C1C-8ACA-C69A40422E08Q35072162-967331E6-ECA7-47F8-9366-45D924795A76Q35108282-F36FD94A-24C2-4E89-9CAF-D412E8CFD472Q35186161-AB67BB82-7772-4449-AF80-DFD9F1BF0F7AQ35186866-20E262A2-A8D5-4CC2-8B77-31697CCFABBEQ35735337-224D4018-78D6-4C4B-AA61-0F60770BD87EQ35833291-A54C8D70-0A21-4A2E-BD13-56E8C27C4DE5Q35947620-0920225C-E150-4360-9FB2-2EF14C616411Q35995836-F107D85F-685F-44FF-BEFC-9ADA6E96A702Q36112513-D6D99302-1361-402A-9BB1-85C180A07B51Q36233245-5C42E284-B5D4-418A-AF0E-8141023DBF35Q36234933-CD7CFCDB-E617-4D44-94BA-5F2E66568C09Q36249259-684BEDE6-3F5D-44C4-A134-53E341EC1D77Q36952561-AFEADB06-ED23-4202-8EF8-87BC2A075D6DQ36957480-E46F846A-90B2-463C-B0B5-9FB67CEA8E9DQ37030672-7F1B8969-2A9C-4B25-968B-6554B35093CCQ37326952-A06CF87D-A146-4D81-8E0A-1F91E9C79358Q37358128-FF2CB523-5320-40CE-AF05-B9B0FA73DB8DQ37604827-45C12135-46F2-4113-9205-301A51E5B9C8Q37704118-115F9636-92F5-48F3-8C86-3B565E39476FQ37795798-9D4C041A-4857-4C6C-BF90-9455A4FF7ABDQ37911498-74A836BB-C898-4CCC-84AF-B1075FB0B914Q37962998-84C193AC-66F6-4B80-8CD2-A9BD8C510E96Q38718073-BB308883-C7A2-4467-BD49-45CFEBFB4B2CQ41603395-DB5A4DD6-6770-4FB3-A4E9-0C19B3BCE820Q41708984-DE3ED190-85FF-41E7-884C-2A870410FD21Q44395927-F1803A78-B23B-4BC5-9371-ADD7C0383284Q47607018-20C51314-D695-426A-A0E2-D2C3B587A33B
P2860
A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A double-blind, non-inferiorit ...... ng a GnRH antagonist protocol.
@ast
A double-blind, non-inferiorit ...... ng a GnRH antagonist protocol.
@en
A double-blind, non-inferiorit ...... ng a GnRH antagonist protocol.
@nl
type
label
A double-blind, non-inferiorit ...... ng a GnRH antagonist protocol.
@ast
A double-blind, non-inferiorit ...... ng a GnRH antagonist protocol.
@en
A double-blind, non-inferiorit ...... ng a GnRH antagonist protocol.
@nl
prefLabel
A double-blind, non-inferiorit ...... ng a GnRH antagonist protocol.
@ast
A double-blind, non-inferiorit ...... ng a GnRH antagonist protocol.
@en
A double-blind, non-inferiorit ...... ng a GnRH antagonist protocol.
@nl
P2093
P2860
P356
P1433
P1476
A double-blind, non-inferiorit ...... ng a GnRH antagonist protocol.
@en
P2093
B C J M Fauser
B M J L Mannaerts
ENGAGE Investigators
P C Ijzerman-Boon
R Boostanfar
P2860
P304
P356
10.1093/HUMREP/DEP291
P407
P50
P577
2009-08-14T00:00:00Z